Use of Certain Prescription Drugs Linked to COVID-19 Mortality | Health, Medicine and Fitness

MONDAY January 10, 2022 (HealthDay News) – A potential COVID-19 survival benefit is suggested in association with the initiation or continuation of an angiotensin converting enzyme (ACE-I) inhibitor, d ” an angiotensin receptor blocker (ARB), or metformin for hospital patients, according to a study published in the December issue of BMJ.

Arthur W. Wallace, MD, Ph.D., of the San Francisco Veterans Affairs Medical Center, and colleagues classified the patterns of use of ACE-I, ARA, beta blockers, metformin , famotidine and remdesivir and captured mortality among 9,532 hospital patients with COVID-19 infection.

Researchers found that stopping an ACE-I was associated with a high risk of death (odds ratio, 1.4), while the risk of death was reduced in association with initiation or use. continuous ACE-I (odds ratios, 0.3 and 0.6, respectively). Statistically significant associations of similar direction and magnitude were observed with the use of ARBs and metformin. Taking into account the pre-existing morbidity and the adjustment of the propensity score, the results remained unchanged.

“Our results not only support the continuation of the drugs ACE-I, ARB and metformin in hospitalized patients with COVID-19, but suggest a benefit for initiation in patients with an indication for treatment,” the authors write. “We also found consistent evidence with the benefits of the same strategy in patients with COVID-19 who are not hospitalized. “

Source link

About Alex S. Crone

Check Also

Top 20 most expensive prescription drugs in 2022

If you thought inflation was high, wait until you hear about rising specialty drug prices. …